

Regulatory Barriers and Harmonization Prospects for Generic Drug Approval in South Africa, Nigeria, Tanzania, and Zimbabwe

K. Supreetha¹, Kishore Rapolu², Murali Krishna Prasad Vallabhaneni³, Pallavi K¹

¹Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutics, Mangalore, India, ²Cronus Pharma Specialities India Pvt Ltd., GMR Aviation SEZ, Hyderabad, Telangana, India, ³Navinta III Inc., Boca Raton, FL, USA

Abstract

The African pharmaceutical market is undergoing rapid transformation, fueled by a rising disease burden, demographic growth, and heightened healthcare needs. Generic medicines – affordable, high-quality alternatives to branded drugs – are central to expanding access to essential treatments. Yet, regulatory requirements for generic drug registration remain highly fragmented across African nations, posing significant hurdles for pharmaceutical companies seeking multi-country entry. This comparative study critically examines the generic drug registration frameworks in South Africa, Nigeria, Tanzania, and Zimbabwe, analyzing dossier formats, approval timelines, fee structures, stability data expectations, and bioequivalence requirements. Key disparities are highlighted, revealing operational inefficiencies that can delay patient access and inflate costs. The findings underscore the urgent need for regulatory harmonization across Africa, offering strategic insights for industry stakeholders and policymakers. In light of ongoing initiatives such as the African Medicines Regulatory Harmonization and the emerging African Medicines Agency, this paper proposes pathways toward streamlined approval processes to accelerate access to affordable generics. A unified regulatory ecosystem could serve as a catalyst for improved public health outcomes and pharmaceutical innovation across the continent.

Key words: African medicines agency harmonization, African regulatory agencies, drug registration challenges in Africa, generic drug approval in Africa, pharmaceutical regulation in Africa, regulatory barriers to generic drugs

INTRODUCTION

Healthcare systems rely heavily on the availability of medicines that are safe, effective, and reasonably priced. Medical products such as pharmaceuticals, vaccines, diagnostic tools, and devices are essential for preventing, detecting, and treating diseases. Ensuring their quality, efficacy, and safety demands robust regulatory oversight, supported by sound scientific principles and enforced through strong legal frameworks. Across Africa, regulatory systems for medicines exhibit profound diversity.^[1-3] According to the World Health Organization (WHO), 54 National Medicines Regulatory Authorities (NMRAs) operate across the continent, each varying widely in organizational structure, mandate, and maturity. Some function as semi-autonomous bodies; others are directly administered by

Ministries of Health. While certain NMRAs oversee only medicinal products, others extend their reach to foods, cosmetics, and medical devices. Despite these variations, ultimate accountability typically rests with National Ministries of Health.^[4] Africa, home to approximately 1.5 billion people across 55 countries, is geographically segmented into five sub-regions: North, West, Middle, East, and Southern Africa [Figure 1]. These sub-regions differ not

Address for correspondence:

Dr. Pallavi K, Department of Pharmaceutics, NGSM Institute of Pharmaceutical Science, Nitte (Deemed to be University), Mangaluru - 575 018, Karnataka, India. Phone: +91-9916369272. E-mail: pallavi.tth@gmail.com; pallavi.k@nitte.edu.in

Received: 05-11-2025

Revised: 10-12-2025

Accepted: 23-12-2025

only in population size and economic development but also in regulatory sophistication, creating a fragmented environment for pharmaceutical registration and market entry.^[5,6]

Generic medicines play an increasingly critical role in African healthcare systems. Offering equivalent quality, safety, and therapeutic efficacy as innovator drugs, generics are vital for controlling public healthcare costs and improving access to essential treatments.^[7] Given that generic drug prices are typically 10–80% lower than those of branded products, ensuring their rapid market entry is both an economic imperative and a public health priority. Every regulatory delay represents a missed opportunity to lower healthcare expenditures and enhance patient outcomes. However, significant challenges persist. Regulatory requirements for generic drug registration differ considerably among African nations in dossier format, evaluation timelines, stability data expectations, and bioequivalence (BE) study demands. This regulatory heterogeneity forces pharmaceutical companies to duplicate efforts, leading to higher costs, extended approval times, and slower access to critical medicines.^[8,9]

This study aims to critically compare the registration requirements for generic medicines in four key African countries, South Africa, Nigeria, Tanzania, and Zimbabwe, focusing on dossier formats, approval timelines, fee structures, and BE considerations. By illuminating the regulator, disparities, and operational hurdles, the paper highlights the pressing need for harmonization initiatives that can streamline registration pathways, promote market access, and ultimately enhance public health across Africa.^[10] In every nation, medical supplies such as medications, vaccinations, blood products, diagnostic tools, and medical gadgets are vital to the provision of healthcare. In each given country, ensuring the safety, effectiveness, quality, and affordability of medical products is essential to advancing patient care and public health. Strong regulatory frameworks are needed to ensure the effectiveness, safety, and quality of medical products as well as to promote trade and socioeconomic development.^[11,12]

Many Africans continue to struggle with limited access to drugs, which has a detrimental impact on many countries' overall health statistics. The availability and affordability of medications, along with other essential medical supplies and equipment, are critical to maintaining and ensuring high standards of patient care in healthcare facilities. One of the biggest obstacles to society acquiring better healthcare services is the lack of access to pharmaceuticals.^[13,14]

Key challenges in African countries

- High burden of infectious and non-infectious diseases: Overwhelms weak healthcare systems and increases medicine demand

- Limited local pharmaceutical manufacturing capacity: Africa produces only 3% of global medicines despite high disease burden
- Heavy reliance on imported medicines and raw materials: 70–90% of medicines are imported, increasing vulnerability to shortages
- Poor and inefficient supply chain systems: Leads to frequent stock-outs, high costs, and circulation of counterfeit drugs
- Government underinvestment in healthcare and pharmaceuticals: Low healthcare budgets, poor policy implementation, and lack of incentives for local manufacturing
- High out-of-pocket healthcare spending: Most people pay for medicines themselves due to limited insurance coverage
- Unfavorable manufacturing conditions: High costs, unreliable electricity, and lack of infrastructure hinder local drug production
- Widespread circulation of fake and counterfeit medicines: Africa accounts for 42% of global cases, endangering public health
- Shortage and migration of healthcare workforce: Limits medicine distribution and effective treatment access
- Lack of effective medicine pricing and regulation: Medicines are often unaffordable and overpriced compared to global standards.^[15-17]

COUNTRY-SPECIFIC REQUIREMENTS

South Africa

Regulatory law: Medicines and Related Substances Control Act No. 101 of 1965

Dossier format: Common technical document (eCTD)/CTD

Language: English

Approval Timeline: 8–24 months

Registration fee: USD 3,370

Stability zone: Zone II (subtropical/Mediterranean).

Stability data required:

- Long-term: 25 ± 2°C/60 ± 5% RH (12 months)
- Accelerated: 40 ± 2°C/75 ± 5% RH (6 months)

The South African Health Products Regulatory Authority (SAHPRA) oversees the safety, effectiveness, and quality of pharmaceuticals and health products for humans and animals. It licenses pharmaceutical establishments, oversees clinical trials, and monitors adverse events and radiation-emitting devices. SAHPRA operates under laws including




Figure 1: African countries by region

the Medicines Act (1965), National Health Act (2003), and Hazardous Substances Act (1973). The Quality and BE Guideline describes how the SAHPRA assesses the safety, effectiveness, and quality of pharmaceutical products. For generic medicines, applicants are required to provide a BE Trial Information Form to support and simplify the review process.^[18-21]

Regulatory approval procedure

The regulatory approval procedure in South Africa involves dossier submission to SAHPRA, followed by administrative screening, quality and bioequivalence evaluation, and GMP verification. Applicants respond to regulatory queries during assessment. Upon satisfactory review and fee payment, marketing authorization is granted, as illustrated in Figure 2.

Nigeria

Regulatory law: NAFDAC Act CAP N1 (LFN) 2004

Dossier format: CTD

Language: English

Approval timeline: 6–12 months

Registration fee: USD 1,100

Stability zone: Zone IVB (Hot/Higher Humidity Zone).

Stability data required:

- Long-term: $30 \pm 2^\circ\text{C}/65 \pm 5\%$ or $75 \pm 5\%$ RH (6 months)
- Accelerated: $40 \pm 2^\circ\text{C}/75 \pm 5\%$ RH (6 months).

The National Agency for Food and Drug Administration and Control (NAFDAC) functions as the central body responsible for regulating pharmaceuticals and biological products in Nigeria. NAFDAC was created by Decree No. 15 of 1993, with further revisions introduced through Decree No. 19 of 1999, and now functions under the NAFDAC Act, Cap N1, Laws of the Federation of Nigeria (2004). The production, importation, exportation, distribution, advertising, sale, and usage of regulated goods, including food, medications, cosmetics, medical equipment, chemicals, and detergents, are all governed by NAFDAC. The “Quality guidelines for the registration of pharmaceutical products” streamline international regulatory procedures by providing rules for regulatory submissions using the CTD format, which complies with International Council for Harmonization standards.^[24,25]

Regulatory approval procedure

In Nigeria, the approval process begins with CTD dossier submission to NAFDAC, followed by document vetting, GMP inspection, laboratory analysis, and bioequivalence assessment. Identified deficiencies are addressed through queries. Successful completion of all stages results in product registration, as shown in Figure 3.

Tanzania

Regulatory law: Tanzania food, drugs and cosmetics act (CAP. 219)




Figure 2: Regulatory approval procedure in South Africa^[22,23]

Dossier format: CTD

Language: English

Approval timeline: 6–18 months


Registration fee: USD 2,000

Stability zone: Zone II (Subtropical/Mediterranean zone).

Stability data required:

- Long-term: $30 \pm 2^\circ\text{C}/65 \pm 5\%$ or $75 \pm 5\%$ RH (12 months)
- Accelerated: $40 \pm 2^\circ\text{C}/75 \pm 5\%$ RH (6 months).

The Tanzania Medicines and Medical Devices Authority (TMDA), established in 2003, oversees the quality, safety, and effectiveness of medicines, medical devices, and associated goods in Tanzania. The Food, Drugs, and Cosmetics Act of 2003 requires pharmaceutical importers to have their products certified by TMDA. The Tanzania Bureau of Standards took over the regulation of food and cosmetics in 2019. For importers and exporters, the “Guidelines for Importation and Exportation of Pharmaceutical Products and Raw Materials, 2011” offer detailed information. Drugs that are generic must be bioequivalent to their reference counterparts. The CTD format is used for regulatory submissions, with five modules covering administrative requirements, quality,



DMS = Document Management System

NAPAMS-NAFDAC Automated Product Administration and Management System

Figure 3: Regulatory approval procedure in Nigeria^[26]

pre-clinical, and clinical data, providing a structured approach for product registration.^[27,28]

Regulatory approval procedure

The regulatory approval pathway in Tanzania includes CTD submission to TMDA, administrative validation, technical evaluation of quality and bioequivalence data, and GMP compliance assessment. Queries are resolved during review. Marketing authorization is issued upon fulfillment of regulatory requirements, as depicted in Figure 4.

Zimbabwe

Regulatory law: Medicines and Allied Substances Control Act [15:03] of 1969

Dossier format: CTD

Language: English

Approval timeline: 12–24 months

Registration fee: USD 2,500

Stability zone: Zone II and IVB (subtropical/Mediterranean zone and hot/higher humidity zone).

Stability data required:

- Long-term: $30 \pm 2^\circ\text{C}/65 \pm 5\%$ or $75 \pm 5\%$ RH (12 months)
- Accelerated: $40 \pm 2^\circ\text{C}/75 \pm 5\%$ RH (6 months).

The Medicines and Allied Substances Control Act (Chapter 15:03) of 1969 established the Medicines Control Authority of Zimbabwe (MCAZ), which is responsible for ensuring the efficacy, safety, and quality of medications and medical equipment. It manages clinical trial approvals, laboratory testing, marketing authorizations, post-marketing surveillance, and manufacturer and distributor licensing. MCAZ evaluates pharmaceutical applications through its Evaluation and Registration Division. Recognized by the WHO and ZAZIBONA, it plays a key role in Zimbabwe's 2021–2025 National Development Strategy. Applicants must submit Form EVF03 in hard copy and MS Word format on CD in accordance with the MCAZ Guideline on Submission of Documentation for Registration of a Multi-Source (Generic) finished pharmaceutical products (FPPs), which is based on the WHO Technical Report Series No. 937, 2006, Annex 7, to register multi-source (generic) FPPs.^[32-34]

Regulatory approval procedure

In Zimbabwe, applicants submit a CTD-based dossier to MCAZ for screening and technical evaluation. The process includes quality assessment, GMP verification, and bioequivalence review. Regulatory queries may be raised before approval. Upon compliance, marketing authorization is granted, as presented in Figure 5.

COMPARATIVE ANALYSIS

A detailed comparative analysis was conducted to evaluate the regulatory requirements for generic drug registration across South Africa, Nigeria, Tanzania, and Zimbabwe. The comparison focused on key operational parameters, including regulatory authorities, legal frameworks, dossier formats, approval timelines, fee structures, stability data expectations, and BE requirements [Table 1].

Regulatory frameworks and dossier formats

All four countries mandate the use of the CTD format for regulatory submissions, with South Africa also accepting the electronic CTD (eCTD). English is the standard submission language across all jurisdictions, facilitating regional accessibility.^[34]

Approval timelines

Approval timelines varied significantly. Nigeria and Tanzania exhibited relatively shorter review periods (6–12 months and

Table 1: Comparative analysis of generic drug registration requirement

Parameter	South Africa	Nigeria	Tanzania	Zimbabwe
Regulatory agency	SAHPRA	NAFDAC	TMDA	MCAZ
Website	https://www.sahpra.org.za/	https://nafdac.gov.ng/	https://www.tmda.go.tz/	https://www.mcaz.co.zw/
Drug law	Act 101 of 1965	NAFDAC act CAP N1 (LFN) 2004	¶TFDC Act (CAP. 219)	¥MASCA (15:03) of 1969
Dossier format	eCTD/CTD	CTD	CTD	CTD
Dossier language	English	English	English	English
Registration validity	5 years	5 years	5 years	5 years
Approval timeline	8–24 months	6–12 months	6–18 months	12–24 months
Manufacturing license	Required	Required	Required	Required
COPP/free sale certificate	Required	Required	Required	Required
Registration fee	\$3,370	\$1,100	\$2,000	\$2,500
GMP inspection validity	3 years	3 years	3 years	3 years
Stability zone	Zone II	Zone IVB	Zone II	Zone II and IVB
Stability data	*LT: 12m/°ACC: 6 m	*LT: 6m/°ACC: 6m	*LT: 12m/°ACC: 6 m	*LT: 12m/°ACC: 6 m
LT conditions	25°C±2/60%±5 RH	30°C±2/65–75% RH	30°C±2/65–75% RH	30°C±2/65–75% RH
ACC conditions	40°C±2/75%±5 RH	40°C±2/75% RH	40°C±2/75% RH	40°C±2/75% RH
BE study requirement	US/EU or SA innovator	US/EU innovator	US/EU innovator	US/EU innovator
BE acceptance criteria	90% °CI of ®AUC and §Cmax: 80–125%	90% °CI of ®AUC and §Cmax: 80–125%	90% °CI of ®AUC and §Cmax: 80–125%	90% °CI of ®AUC and §Cmax: 80–125%

*LT: Long term, °ACC: Accelerated, °CI: Confidence interval, ®AUC: Area under curve, §C_{max}: Maximum concentration, ¶TFDC: Tanzania food, drugs, and cosmetics, ¥MASCA: Medicines and allied substances control act

6–18 months, respectively), while South Africa and Zimbabwe demonstrated longer timelines (8–24 months and 12–24 months, respectively), posing potential delays for market access.

Registration fees

Registration fees ranged widely. Nigeria offered the most economical pathway (USD 1,100), whereas South Africa imposed the highest fee (USD 3,370). Tanzania and Zimbabwe fell in the moderate range, with fees of USD 2,000 and USD 2,500, respectively.

Stability requirements

Stability zone classifications and requirements differed between regions. South Africa and Tanzania primarily operate under Zone II conditions (subtropical/Mediterranean), while Nigeria and Zimbabwe apply Zone IVB conditions (hot/higher humidity zones). Notably, Zimbabwe requires compliance with both Zone II and IVB conditions.^[37,38]

BE requirements

All four regulatory bodies mandate demonstration of BE to reference products sourced from recognized

markets (US, European Union [EU], or locally registered innovators). Acceptance criteria uniformly followed the 90% confidence interval for area under curve and maximum concentration within 80–125%, consistent with international standards.^[39,40]

Overall, while a degree of alignment exists in dossier structures and BE criteria, significant disparities in approval timelines, registration fees, and stability data requirements present operational challenges for pharmaceutical companies seeking multi-country access across Africa.

DISCUSSION

South Africa, Nigeria, Tanzania, and Zimbabwe each have distinct pharmaceutical regulatory frameworks, yet they face challenges in aligning with global standards. In contrast, the EU has established stringent regulatory frameworks that set a high benchmark for drug development, processing, and approval. The European Medicines Agency (EMA), a decentralized body of the EU, is responsible for assessing applications for European marketing authorization through




Figure 4: Regulatory approval procedure in Tanzania^[29-31]

the centralized procedure, where companies submit a single marketing authorization application. The EMA continuously monitors the safety of medicines through a robust pharmacovigilance program to ensure compliance and public safety. The EU pharmaceutical legislation prioritizes public health while facilitating the free movement of medicinal products across member states. Compared to regulatory frameworks in South Africa, Nigeria, Tanzania, and Zimbabwe, the EU system is more centralized, with harmonized approval processes that streamline market access.^[41]

Pharmaceutical market growth in Africa

Africa's pharmaceutical market is undergoing rapid expansion, driven by population growth, urbanization, economic development, and the rising burden of non-communicable and infectious diseases. Although the continent's healthcare infrastructure remains underdeveloped compared to other global regions, growing investment, political commitment, and increased public health awareness are creating substantial opportunities for the pharmaceutical sector growth.

The COVID-19 pandemic served as a critical inflection point, exposing vulnerabilities in Africa’s health systems and underscoring the urgent need for self-sufficiency in healthcare products. The pandemic accelerated initiatives that had previously been slow to gain momentum, notably the push for regulatory harmonization and local pharmaceutical manufacturing. With oncology drugs and chronic disease treatments leading market expansion, the African pharmaceutical industry is poised for sustained growth, provided regulatory systems can adapt to support innovation and ensure equitable access.^[42,43]

Regulatory harmonization in Africa

Africa’s nations are represented by the 55 member states that make up the African Union (AU), a continental organization. The Organization of African Unity, which existed from 1963 until 1999, was superseded by the AU in 2002. Key components of the AU’s structure include the Regional Economic Communities and the African Peer Review Mechanism. The AU established the African Medicines Agency (AMA) to increase access to high-quality, safe, and effective medications, medical supplies, and health technologies throughout the continent by strengthening the regulatory capacities of African countries.^[44]

The African Medicines Regulatory Harmonization (AMRH) Initiative was established in 2009 with the intention of standardizing laws across the continent and enhancing national regulatory systems. The goal of this initiative is to improve access to quality-assured medications by standardizing regional regulatory procedures. The East African Community (EAC) Medicines Regulatory Harmonization (MRH), the Southern African Development Community (SADC)/ZaZiBoNa MRH, and the Economic Community of West African States (ECOWAS) MRH are the three primary regional initiatives under the AMRH, as indicated in Table 2. These initiatives aim to establish a common framework and standardize regulatory procedures within their individual regions. Together, they supported the creation of the AMA, which aims to enhance access to high-quality medications throughout the continent by strengthening and streamlining Africa’s pharmaceutical regulations.^[45-48]

Regulatory fragmentation and its implications

This study highlights considerable regulatory fragmentation across South Africa, Nigeria, Tanzania, and Zimbabwe. Although dossier structures (CTD format) and BE acceptance criteria have largely converged with international standards, critical divergences remain in approval timelines, registration costs, and stability data requirements.

Approval timelines varied by as much as 18 months between countries, significantly impacting the speed at which generic medicines become available to patients. Delays in regulatory approval not only hinder public health improvements but also increase costs for manufacturers, discouraging investment




Figure 5: Regulatory approval procedure in Zimbabwe^[35]

Table 2: EAC, SADC, and ECOWAS country categories

Regional economic communities	Countries
East African community	Kenya, Uganda, Tanzania, Rwanda, Burundi, South Sudan
Southern African Development Community (SADC)	South Africa, Botswana, Namibia, Angola, Zimbabwe, Mozambique, Zambia, Lesotho, Eswatini (Swaziland), Malawi, Seychelles, Mauritius, Democratic Republic of Congo, Tanzania
Economic community of West African states (ECOWAS)	Nigeria, Ghana, Senegal, Côte d’Ivoire, Benin, Burkina Faso, Cape Verde, Gambia, Guinea, Guinea-Bissau, Liberia, Mali, Niger, Sierra Leone, Togo

and reducing the affordability of medicines. Similarly, large disparities in registration fees create financial barriers for small and medium-sized pharmaceutical companies seeking multi-country market entry.

The lack of standardized stability zone requirements and differing interpretations of long-term and accelerated data further complicate the process, requiring companies to conduct redundant studies or maintain multiple stability profiles, thus escalating development costs.

Without greater regulatory convergence, the operational and financial inefficiencies associated with fragmented approval processes are likely to persist, limiting the benefits of expanded pharmaceutical production capacity and market growth.

Emerging initiatives toward regulatory harmonization

Recognizing the challenges posed by regulatory fragmentation, African nations have launched several regional initiatives aimed at harmonizing medicines regulation. The AMRH initiative, established in 2009, seeks to strengthen national regulatory capacities and streamline approval processes through regional collaboration.

The Economic Community of West AMRH (ECOWAS-MRH), the SADC-ZAZIBONA, and the East AMRH (EAC-MRH) are three major regional harmonization projects that have made significant progress in coordinating technical requirements, creating joint assessment procedures, and constructing mutual recognition frameworks.

The establishment of the AMA under the AU further represents a significant step toward continent-wide regulatory harmonization. AMA's mandate to coordinate regulatory activities, set common standards, and support national authorities could profoundly transform Africa's pharmaceutical landscape by reducing duplication, speeding access to generics, and attracting greater investment.^[49-50]

Pathways to accelerate access to generics

Building on current initiatives, several strategic actions could further accelerate access to generic medicines in Africa:

Standardizing registration fees and approval timelines

Establishing regionally harmonized fee structures and target review timelines would reduce market entry barriers, particularly for smaller manufacturers.

Mutual recognition agreements

Wider adoption of mutual recognition of regulatory decisions across African countries would minimize

redundant assessments and facilitate faster product approvals.

Unified stability zone guidelines

Adopting harmonized stability testing requirements (aligned with WHO climatic zones) would streamline dossier preparation and reduce unnecessary testing burdens.

Digitalization and centralized platforms

Expansion of electronic submission systems (eCTD) and centralized application platforms could enhance regulatory efficiency and transparency across multiple countries.

Progress in these areas would not only facilitate faster access to affordable medicines but also strengthen Africa's resilience to future health emergencies by supporting a more self-reliant pharmaceutical ecosystem.^[51]

This comparative study highlights the significant regulatory differences in generic drug registration requirements among South Africa, Nigeria, Tanzania, and Zimbabwe. The analysis reveals notable differences in dossier formats, approval timelines, stability data requirements, BE study expectations, and registration fees, all of which present operational and strategic challenges for pharmaceutical companies aiming for multi-country market access.

Approval timelines emerged as a major point of variation, with Nigeria and Tanzania offering relatively faster review times (6–18 months), while South Africa and Zimbabwe demonstrated longer approval windows (8–24 months). These delays in market access can increase costs and limit the timely availability of affordable generic medicines, undermining public health objectives. Registration fees also showed considerable differences. South Africa and Zimbabwe charged the highest fees, Tanzania maintained moderate fees, and Nigeria remained the most economical registration destination.

To address these regulatory discrepancies and inefficiencies, regional harmonization initiatives such as the AMRH and the AMA have been introduced. In addition, the implementation of globally recognized dossier formats like the CTD has facilitated better alignment with international regulatory expectations and reduced the redundancy in dossier compilation.

However, full harmonization across Africa remains a work in progress. While progress has been made through regional initiatives such as EAC-MRH, SADC-ZAZIBONA, and ECOWAS-MRH, further integration and mutual recognition of regulatory decisions are essential. Standardizing technical requirements, streamlining approval timelines, and establishing regionally harmonized fee structures could dramatically improve access to affordable, quality-assured generic medicines across Africa.

This study underscores the importance of harmonization in reducing regulatory burdens, accelerating market access, and ultimately enhancing public health outcomes. As African markets continue to expand, collaborative regulatory frameworks will be pivotal in ensuring faster, more equitable access to essential medicines across the continent.

CONCLUSION

Achieving equitable access to high-quality, affordable generic medicines is essential for strengthening healthcare systems across Africa. However, this study highlights that significant regulatory fragmentation persists among major African markets, creating operational barriers, prolonging approval timelines, and increasing the cost of bringing generics to patients. While initiatives such as the AMRH and the AMA offer promising pathways toward greater convergence, sustained commitment is required to fully realize their potential. Standardizing dossier requirements, harmonizing stability testing expectations, aligning fee structures, and advancing mutual recognition frameworks could substantially reduce duplication and streamline market access for generic medicines across the continent. Generic medicines, by providing cost-effective alternatives to branded drugs, have the power to transform public health outcomes and reduce healthcare expenditure. As Africa's pharmaceutical market continues to grow, regulatory harmonization must be prioritized as a critical enabler of innovation, investment, and improved patient care. Strategic collaboration between regulators, industry stakeholders, and policymakers will be essential to unlock the full potential of generics in Africa – ensuring faster, more equitable access to essential medicines for all.

REFERENCES

- Yenet A, Nibret G, Tegegne BA. Challenges to the availability and affordability of essential medicines in African countries: A scoping review. *Clinicoecon Outcomes Res* 2023;15:443-58.
- Bansal D, Purohit VK. Accessibility and use of essential medicines in health care: Current progress and challenges in India. *J Pharmacol Pharmacother* 2013;4:13-9.
- Dylst P, Vulto A, Simoens S. Overcoming challenges in market access of generic medicines in the European Union. *J Gen Med* 2012;9:21-8.
- List of National Regulatory Authorities (NRAs) Operating at Maturity Level 3 (ML3) and Maturity Level 4 (ML4). Available from: <https://www.who.int/publications/m/item/list-of-nras-operating-at-ml3-and-ml4> [Last accessed on 2024 Oct 25].
- Ndomondo-Sigonda M, Miot J, Naidoo S, Dodoo A, Kaale E. Medicines regulation in Africa: Current State and opportunities. *Pharmaceut Med* 2017;31:383-97.
- African Population. Available from: <https://www.worldometers.info/world/population/africa/population> [Last accessed on 2024 Oct 25].
- Promoting the Use of Quality-Assured Generic and Biosimilar Medicines. Available from: <https://apps.who.int/iris/bitstream/handle/10665/341900/9789240024915-eng.pdf> [Last accessed on 2024 Oct 25].
- Expanding Bioequivalence Studies in Africa. Available from: <https://www.usp.org/global-public-health/projects/bioequivalence-studies-africa> [Last accessed on 2024 Oct 25].
- Rafi N, Ds S, Narayanan VA. Regulatory requirements and registration procedure for generic drugs in USA. *Indian J Pharm Educ Res* 2018;52:544-9.
- African Union: Member States. Available from: https://au.int/en/member_states/countryprofiles2 [Last accessed on 2024 Oct 25].
- Narsai K, Williams A, Mantel-Teeuwisse AK. Impact of regulatory requirements on medicine registration in African countries-perceptions and experiences of pharmaceutical companies in South Africa. *South Med Rev* 2012;5:31-7.
- Moran M, Strub-Wourgaft N, Guzman J, Boulet P, Wu L, Pecoul B. Registering new drugs for low-income countries: The African challenge. *PLoS Med* 2011;8:e1000411.
- Health Products Policy and Standards. Available from: <https://www.who.int/teams/health/product/policy/and/standards/assistive/and/medical-technology> [Last accessed on 2024 Oct 25].
- Lane J, Nakambale H, Kadakia A, Dambisya Y, Stergachis A, Odoch WD. A systematic scoping review of medicine availability and affordability in Africa. *BMC Health Serv Res* 2024;24:91.
- Communicable and Non-Communicable Diseases in Africa in 2021/22. Available from: <https://www.afro.who.int/publications/communicable-and-non-communicable-diseases-africa-202122> [Last accessed on 2024 Oct 25].
- African Pharmaceutical Sector Landscape Analysis. Available from: https://www.commerce.uct.ac.za/sites/default/files/media/documents/commerce_uct_ac_za/470/pharmaceutical-landscape-analysis-final-as-at-12-dec-2024.pdf [Last accessed on 2024 Oct 25].
- Ejekam CS, Emeje M, Lukulay P, Uche CR, Odibeli O, Sanusi O, *et al.* A call to action: Securing an uninterrupted supply of Africa's medical products and technologies post COVID-19. *J Public Health Policy* 2023;44:276-84.
- SAHPRA. Available from: <https://www.sahpra.org.za> [Last accessed on 2024 Nov 27].
- Legislative and other Mandates. Available from: <https://www.sahpra.org.za/who/we/are/#:~:text=sahpra%20is%20the%20regulatory%20authority,and%20the%20conduct%20of%20clinical> [Last accessed on 2024 Nov 27].
- SAHPRA Quality and Bioequivalence Guidelines. Available from: https://www.sahpra.org.za/wp-content/uploads/2020/02/2.02_quality-and_bioequivalence-guideline_jul19_v7-1.pdf [Last accessed on 2024 Oct 25].
- Keyter A, Salek S, Danks L, Nkambule P,

- Semete-Makokotlela B, Walker S. South African regulatory authority: The impact of reliance on the review process leading to improved patient access. *Front Pharmacol* 2021;12:699063.
22. Moeti L, Litedu M, Joubert J. Regulatory registration timelines of generic medicines in South Africa: Assessment of the performance of SAHPRA between 2011 and 2022. *J Pharm Policy Pract* 2023;16:34.
 23. Regulatory & Market Profile of Nigeria. Available from: https://pharmexcil.com/uploadfile/ufiles/nigeria_regulatory_market_profile.pdf [Last accessed on 2024 Nov 27].
 24. Quality Guidelines for the Registration of Pharmaceutical Products For human Use in Nigeria. Available from: https://www.nafdac.gov.ng/wpcontent/uploads/files/resources/guidelines/r_and_r_guidelines/general/quality/guidelines/for/registration/of/pharmaceutical/products26381.pdf [Last accessed on 2024 Dec 12].
 25. Drug Registration and Regulatory Affairs (DRR) Directorate. Available from: <https://nafdac.gov.ng/about/nafdac/nafdac/organisation/directorates/drug/regulations/registration-drr-directorate> [Last accessed on 2024 Dec 12].
 26. TMDA Profile. Available from: <https://www.tmda.go.tz/pages/tfda-profile> [Last accessed on 2024 Nov 04].
 27. Guidelines on Submission of Documentation for Registration of Human Pharmaceutical Products. Available from: <https://www.tmda.go.tz/uploads/publications/en1558431181/guidelines%20on%20submission%20of%20documentation%20for%20registration%20of%20medicines.pdf> [Last accessed on 2024 Nov 04].
 28. Krishna JM, Reddy DN, Nagabhushanam MV, Bonthagarala B, Ramakrishna G. Drug registration process followed in Tanzania. *World J Pharm Res* 2018;7:343-8.
 29. Mashingia J, Ngum N, Ndomondo-Sigonda M, Kermad A, Bujar M, Salek S, *et al.* Regulatory performance of the East African Community joint assessment procedure: The way forward for regulatory systems strengthening. *Regul Toxicol Pharmacol* 2023;31:105383.
 30. Kamaraj R, Buruwe LM. Comparative study of regulatory requirements and marketing authorization for medicinal products in European Union and Zimbabwe. *Asian J Pharm Clin Res* 2018;11:1-8.
 31. Guideline on Submission of Documentation For Registration of a Multisource (Generic) Finished Pharmaceutical Product (Fpp): Quality Part in the Common Technical Document (Ctd) Format. Available from: <https://www.mcaz.co.zw/wp/content/uploads/2021/11/ctd-guidelines-1.pdf> [Last accessed on 2024 Dec 24].
 32. Nerkar P, Patil A, Shaha G, Deshmukh V. Comparative study of regulatory requirement for preparation of dossier for registration of oral solid dosage form in Zimbabwe and Myanmar. *Int J Drug Reg Affairs* 2023;11:68-74.
 33. Sithole T, Salek S, Mahlangu G, Walker S. Comparison of the registration process of the medicines control authority of Zimbabwe with Australia, Canada, Singapore, and Switzerland: Benchmarking best practices. *Expert Rev Clin Pharmacol* 2021;15:109-19.
 34. The Common Technical Document for the Registration of Pharmaceuticals for Human use: Quality - M4Q(R1). Available from: https://database.ich.org/sites/default/files/m4q_r1_guideline.pdf [Last accessed on 2024 Oct 25].
 35. Climatic Zones for Stability Studies. Available from: <https://www.pharmaguideline.com/2010/12/different/climatic/zones/for/stability.html> [Last accessed on 2024 Oct 25].
 36. Autade A, Patil V. Study on regulatory requirements for conducting bioequivalence/bioavailability studies in USA, Europe, Canada and India. *Int J Sci Dev Res* 2023;8:232-9.
 37. European Medicines Agency. Available from: <https://www.ema.europa.eu/en/homepage> [Last accessed on 2024 Oct 25].
 38. African Pharmaceutical Market Outlook; 2024 Edition. Available from: <https://www.goldsteinresearch.com/report/africa-pharmaceutical/industry/market/size-forecast> [Last accessed on 2024 Dec 25].
 39. Pharmaceuticals - Africa. Available from: <https://www.statista.com/outlook/hmo/pharmaceuticals/africa> [Last accessed on 2024 Oct 25].
 40. Sithole T, Ngum N, Owusu-Asante M, Walker S, Salek S. Comparison of three regional medicines regulatory harmonisation initiatives in Africa: Opportunities for improvement and alignment. *Int J Health Policy Manag* 2024;13:8070.
 41. The East African Community Medicines Regulatory Harmonization (EAC-MRH) Programme. Available from: <https://www.eac.int/mrh> [Last accessed on 2024 Oct 25].
 42. Southern African Development Community. Available from: <https://www.sadc.int/latest/news/sadc/helps/increase/availability/quality/assured/medicines-patients-region> [Last accessed on 2024 Oct 25].
 43. Economic Community of West African States (ECOWAS). Available from: <https://ustr.gov/countries/regions/africa/regional/economic/communities/rec/economic-community-west-african-states> [Last accessed on 2024 Oct 25].
 44. African Medicines Agency (AMA). Available from: <https://www.nepad.org/microsite/african-medicines-agency-ama> [Last accessed on 2024 Oct 25].
 45. Mastan S, Latha TB, Ajay S. The basic regulatory considerations and prospects for conducting bioavailability/bioequivalence (BA/BE) studies - an overview. *Comp Eff Res* 2011;1:1-25.
 46. Macdonald JC, Isom DC, Evans DD, Page KJ. Digital innovation in medicinal product regulatory submission, review, and approvals to create a dynamic regulatory ecosystem-are we ready for a revolution? *Front Med* 2021;8:660808.
 47. Stability Testing of New Drug Substances and Products Q1A (R2). Available from: <https://share.google/hxcvkdvykvb1k5tytm> [Last accessed on 2024 Oct 25].

48. Sai Hanuja G, Sai Kumari B, Nagabhushanam MV, Nagarjuna Reddy D, Bonthagarala B. Regulatory requirements for registration of generic drugs in “BRICS” Countries. *Int J Pharm Sci Health Care* 2016;6:20-40.
49. McAuslane N, Leong J, Liberti L, Walker S. The benefit-risk assessment of medicines: Experience of a consortium of medium-sized regulatory authorities. *Ther Innov Reg Sci* 2017;51:635-44.
50. Bujar M, McAuslane N, Walker SR, Salek S. Evaluating quality of decision-making processes in medicines’ development, regulatory review, and health technology assessment: A systematic review of the literature. *Front Pharmacol* 2017;8:189.
51. Keyter A, Banoo S, Salek S, Walker S. The South African regulatory system: Past, present, and future. *Front Pharmacol* 2018b;9:1407.

Source of Support: Nil. **Conflicts of Interest:** None declared.